Project Grant 20267043646789
- Federal Grant Award Summary Giner, Inc. received a $181,429 Project Grant from the National Institute of Food and Agriculture (NIFA) under the Small Business Innovation Research (SBIR) Program (CFDA 10.212), awarded September 15, 2025, with completion targeted for May 14, 2026. The award supports the development and testing of a bacteriophage-based antimicrobial product designed to address bovine mastitis, a widespread bacterial infection affecting approximately 30% of dairy cattle during...
- This $649,896.00 project grant was awarded on April 15, 2025 by the U.S. Department of Agriculture's National Institute of Food and Agriculture (NIFA) under the Agriculture and Food Research Initiative (CFDA 10.310). The grant supports the development and testing of an mRNA vaccine cocktail to provide broad protection against influenza A viruses in livestock, particularly pigs and cattle. The mRNA vaccine will be delivered using a novel class of peptide-based cationic nanoparticles designed...
- The Department of Agriculture National Institute of Food and Agriculture awarded The Pennsylvania State University $180,000 on May 1, 2026, under the Agriculture and Food Research Initiative (AFRI, CFDA 10.310) to conduct genomic and epidemiological research on antimicrobial resistance in bacteria causing mastitis on dairy farms, with a focus on Puerto Rico operations, and to develop bilingual educational materials translating that research into farmer-facing resources. The project combines...
- The Department of Agriculture Animal and Plant Health Inspection Service awarded Colorado State University a $2,015,677 cooperative agreement on February 2, 2026, to develop a novel probiotic-based vaccine protecting poultry from highly pathogenic avian influenza. The award funds work under the Plant and Animal Disease, Pest Control, and Animal Care program (CFDA 10.025). The project will construct vaccine candidates using Lactobacillus acidophilus as a platform and test them for...
- The National Institute of Allergy and Infectious Diseases awarded Iaso Therapeutics Inc. $599,998 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a multi-antigen Staphylococcus aureus vaccine using a proprietary mutant bacteriophage platform. Iaso will conduct two research aims over the period of performance through June 30, 2028. In Aim 1, the company will evaluate the protective efficacy of an MQB-PNAG26 conjugate vaccine in a S. aureus...
- Federal Grant Award Summary Tetmedical, Inc. received a $181,392 Phase I Small Business Innovation Research (SBIR) Project Grant (CFDA 10.212) from the U.S. Department of Agriculture's National Institute of Food and Agriculture (NIFA), awarded on August 15, 2025, with completion targeted for April 14, 2026. The company is developing a rapid, point-of-care (POC) diagnostic test for Highly Pathogenic Avian Influenza (HPAI) H5N1 utilizing its proprietary Tethered Enzyme Technology (TET) platform....
- Federal Grant Award Summary Membrane Protective Technologies, Inc. received a $181,500 Phase I Project Grant award from the National Institute of Food and Agriculture (NIFA) under the Small Business Innovation Research (SBIR) Program (CFDA 10.212), effective August 15, 2025, with a completion date of April 14, 2026. The award supports development of plant-based semen extenders for bull sperm cryopreservation to replace traditional animal-derived products such as egg yolk and whole milk. The...
- The Department of Agriculture National Institute of Food and Agriculture awarded North Dakota State University $591,500 under the Agriculture and Food Research Initiative (CFDA 10.310) on May 15, 2026, to develop a web-based vaccine discovery tool for identifying promising vaccine targets against bacterial pathogens that threaten U.S. catfish farming. The project will combine proprietary and public pathogen genetic sequence data to produce ranked candidate vaccine lists for three key bacterial...
- The Department of Agriculture Animal and Plant Health Inspection Service awarded the University of Georgia Research Foundation, Inc. a cooperative agreement totaling $1,999,873 on February 2, 2026, under the Plant and Animal Disease, Pest Control, and Animal Care program (CFDA 10.025). The award funds development of the first U.S.-approved, mass-vaccination-ready modified live virus (MLV) vaccine against highly pathogenic avian influenza (HPAI) for commercial poultry, specifically layer and...
- The Department of Agriculture Animal and Plant Health Inspection Service awarded a Cooperative Agreement totaling $810,568 to the Regents of the University of Minnesota on February 2, 2026, under the Plant and Animal Disease, Pest Control, and Animal Care program (CFDA 10.025). The award funds development and efficacy assessment of a novel lactococcal-phage vaccine to protect poultry from highly pathogenic avian influenza H5N1 Clade 2.3.4.4B. The vaccine will express hemagglutinin and M2E...
The Department of Agriculture National Institute of Food and Agriculture awarded Pentamer Biologics LLC $649,548 on September 1, 2026, under the Small Business Innovation Research (SBIR) Program (CFDA 10.212) to develop and validate a vaccine against Staphylococcus aureus mastitis in dairy cattle. The recipient will optimize and scale vaccine production in the laboratory and establish the optimal route of udder delivery for immune induction. The vaccine is a protein-based formulation designed to induce both systemic and local immunity in milk to prevent bacterial colonization and clinical mastitis. Building on Phase I outcomes, the work includes a large field trial to verify vaccine design and establish a path to licensure, supporting challenge trials necessary for regulatory approval. Mastitis causes annual economic losses of up to $20 billion in dairy cattle worldwide; an effective licensed vaccine will reduce economic burdens on farmers while improving animal welfare and food production quality. Performance occurs in Longwood, Florida, with a period of performance through August 31, 2028. Pentamer Biologics is a small business subsidiary working toward commercialization of the innovation. This Phase II award continues research begun under a prior Phase I grant, focusing on transforming scientific discovery into a product with commercial potential and societal benefit aligned with USDA NIFA's agricultural research mission.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $649.5k | 8/31/26 |